Sandia is developing a panel of immunoassays enabling detection of viral antigens (Ags) and anti-SARS-CoV-2 antibodies (Abs) produced by the host in response to infection. These immunoassays will be implemented Sandia’s portable SpinDx platform, which also offers rapid detection without need for sample preparation. A newer version of SpinDx adds the capability to detect nucleic acid markers using a LAMP assay. Simultaneous detection of viral RNA, combined with the detection of host response to infection via immunoassays, will be a powerful way to diagnose COVID-19 at all stages of disease. Moreover, this combination of assay types would enable us to both positively identify SARS-CoV-2 and rule out influenza or other coronaviruses.

Centrifugal microfluidic platform for ultrasensitive detection of
botulinum toxin
An innovative centrifugal microfluidic immunoassay platform (SpinDx) to address the urgent biodefense and public health need for ultrasensitive point-of-care/incident detection of botulinum toxin.

Koh, C., Schaff, U.Y., Piccini, M. E., Stanker, L.H., Cheng, L.W., Ravichandran, E., Singh, B., Sommer, G.J., and Singh, A.K. Centrifugal microfluidic platform for ultrasensitive detection of botulinum toxin. Analytical chemistry, 87(2), 922–928.

Integrated LAMP and immunoassay platform for diarrheal disease detection
A centrifugal microfluidic platform that combines ultrasensitive immunoassay and isothermal amplification-based screening for the orthogonal detection of both protein and nucleic acid targets at the point-of-care.

Phaneuf, C. R., Mangadu, B., Tran, H. M., Light, Y. K., Sinha, A., Charbonier, F. W., Eckles, T. P., Singh, A. K., & Koh, C. Y. (2018). Integrated LAMP and immunoassay platform for diarrheal disease detection. Biosensors & bioelectronics, 120, 93–101. 

View related technologies available for licensing:  
SpinDx™: Point-of-Care Diagnostics Using Centrifugal Microfluidics

SAND2020-7652 W